Previous 10 | Next 10 |
International Stem Cell Corporation press release (OTC:ISCO): Q1 GAAP EPS of $0.00. Revenue of $2.02M (+21.7% Y/Y). For further details see: International Stem Cell Corporation GAAP EPS of $0.00, revenue of $2.02M
SAN DIEGO, CA / ACCESSWIRE / May 17, 2022 / International Stem Cell Corporation (OTC PINK:ISCO) ( www.internationalstemcell.com ) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today pro...
International Stem Cell Corporation press release (OTC:ISCO): FY GAAP EPS of -$0.11. Revenue of $7.18M (+0.7% Y/Y). For further details see: International Stem Cell Corporation GAAP EPS of -$0.11, revenue of $7.18M
SAN DIEGO, CA / ACCESSWIRE / March 30, 2022 / International Stem Cell Corporation (OTCQX:ISCO) ( www.internationalstemcell.com ) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provid...
LONDON, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a neuropharmaceutical company focused on psychedelic-assisted therapies, announces that Mr. Paul Maier has been appointed as a no...
CARLSBAD, CA / ACCESSWIRE / June 30, 2021 / International Stem Cell Corporation (OTCQB:ISCO) ( www.internationalstemcell.com ) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today succ...
CARLSBAD, CA / ACCESSWIRE / November 15, 2019 / International Stem Cell Corporation (OTCQB:ISCO) ( www.internationalstemcell.com ) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today an...
CARLSBAD, Calif., May 17, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) ( www.internationalstemcell.com ) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, toda...
CARLSBAD, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that it has been valued ...
CARLSBAD, Calif., April 29, 2019 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQX: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced t...
News, Short Squeeze, Breakout and More Instantly...
International Stem Cell Corp Company Name:
ISCO Stock Symbol:
OTCMKTS Market:
Community Bancorp Inc Vermont (CMTV) is expected to report for Q4 2023 CISO Global, Inc (CISO) is expected to report for Q4 2023 TCTM Kids IT Education Inc. (TCTM) is expected to report for quarter end 2023-12-31 Generation Income Properties Inc. (GIPR) is expected to report for quart...
Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31 Hongchang International Co Ltd Com (New) (HCIL) is expected to report for Q4 2023 BioStem Technologies Inc (BSEM) is expected to report $0.47 for Q4 2023 Nicox SA (NICXF) is expected to report $-0.07 for Q4 2023 ...
Volcon Inc. (VLCN) is expected to report for Q4 2023 Tenaga Nasional Bhd ADR (TNABY) is expected to report for quarter end 2023-12-31 Hesai Group (HSAI) is expected to report for Q4 2023 Intrusion Inc. (INTZ) is expected to report $-0.14 for Q4 2023 Eliem Therapeutics Inc (ELYM) i...